Thermo Fisher Scientific Inc (NYSE:TMO) is reporting third quarter earnings results on Wednesday 21st October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 4.31 per share.
For the full year, analysts predict revenues of $ 28920.30 million, while looking forward to income of $ 15.92 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 26,610.00 million ~ $ 27,010.00 million, where as bottomline are predicted in a range of $ 13.49 ~ $ 13.67 per share
Click Here For More Historical Outlooks Of Thermo Fisher Scientific Inc
Previous Quarter Performance
Thermo Fisher Scientific Inc unveiled income for the second quarter of $ 2.90 per share, from the revenue of $ 6,917.00 million, On adjusted basis, TMO reported income for the quarter of $ 3.89 per share. The quarterly earnings escalated 4.69 percent while revenues improved 9.52 percent compared with the same quarter last year. According to street consensus, TMO was expected to report 2Q20 income of $ 2.84 per share from revenue of $ 6134.16 million. The bottom line results beat street analysts by $ 1.05 or 36.97 percent, at the same time, top line results outshined analysts by $ 782.84 million or 12.76 percent.
Stock Performance
Shares of Thermo Fisher Scientific Inc traded up $ 3.56 or 0.77 percent on Tuesday, reaching $ 464.85 with volume of 941.70 thousand shares. Thermo Fisher Scientific Inc has traded high as $ 470.38 and has cracked $ 461.61 on the downward trend
The closing price of $ 464.85, representing a 84.36 % increase from the 52 week low of $ 250.21 and a 2.65 % decrease over the 52 week high of $ 473.84.
The company has a market capital of $ 183.89 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 17th September 2020, maintained by Needham & Company LLC at Buy rating, with $ 477.00 target price.
- On 14th September 2020, initiated by Morgan Stanley at Overweight rating, with $ 485.00 target price.
- On 11th September 2020, maintained by Credit Suisse Group at Neutral rating, with $ 432.00 target price.
- On 11th September 2020, maintained by SVB Leerink at Outperform rating, with $ 470.00 target price.
- On 11th September 2020, maintained by Bank of America at Buy rating, with $ 480.00 target price.
Conference Call
Thermo Fisher Scientific Inc will be hosting a conference call at 8:30 AM eastern time on 21st October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.thermofisher.com
Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.
